ArticleLife (Basel, Switzerland)2026
Serial Presepsin Measurement as a Predictor of In-Hospital Mortality in Older Adults with Hip Fractures.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serial presepsin measurements were evaluated for their prognostic value compared with conventional laboratory markers in predicting in-hospital mortality among older adults with hip fractures. This prospective observational study included 85 patients aged ≥65 years admitted with acute hip fractures between December 2025 and May 2026. Residual serum remaining after routine clinical laboratory sampling was obtained on admission (Day 1), Day 3, and Day 5; serum presepsin was measured by commercial ELISA, and routine parameters (C-reactive protein [CRP], white blood cell count, lymphocytes, monocytes, platelets, and liver enzymes) were analysed in the hospital laboratory. Renal function was assessed by serial creatinine and estimated glomerular filtration rate (eGFR). Patients were classified as survivors or non-survivors according to in-hospital outcome. Temporal trajectories were modelled with a linear mixed-effects model fitted to log-transformed presepsin, receiver operating characteristic (ROC) analysis assessed predictive performance, and internal validity was examined by bootstrap resampling. Of the 85 patients, 68 survived and 17 died during hospitalization; all deaths occurred between hospital days 5 and 12. Presepsin diverged progressively between groups, reaching significantly higher concentrations in non-survivors by Day 5 (median 207.70 vs. 147.21 ng/L;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.